Compare BioNTech SE - ADR (BNTX) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Canadian Natural Resources Ltd. — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Canadian Natural Resources Ltd. trades at $47.64 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 4.2× BioNTech SE - ADR's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CNQ | |
|---|---|---|
Market Cap | $23.31B | $98.11B |
Sector | Health | Energy |
52-Week High | $119.34 | $50.55 |
52-Week Low | $83.89 | $29.31 |
Enterprise Value | $6.60B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Canadian Natural Resources (CNQ) trades at $47.65, up 0.85% with strong technical momentum. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.53 versus $1.43 expected, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 11.82 and EV/EBITDA of 6.35, while profitability metrics impress with 26.69% ROE and 22.87% net margin. Recent news highlights record production and dividend consistency.
CNQ presents a compelling investment case with strong operational performance, attractive valuation, and shareholder returns through dividends. The primary risks include oil price volatility and execution challenges in capital projects. Analyst consensus remains strongly bullish with 27 buy ratings and no sell recommendations, supporting upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
